| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,250,000,000 |
| Market
Cap: |
100.60(B) |
| Last
Volume: |
14,535,649 |
Avg
Vol: |
11,963,293 |
| 52
Week Range: |
$43.67 - $69.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 11.9 |
|
| Guru Rank Number : 97 |
| Guru Rank Value : 8.6 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Co.'s primary products include: Revlimid®, in which Revlimid (lenalidomide) is an oral immunomodulatory drug that in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma; and Eliquis®, in which Eliquis (apixaban) is an oral Factor Xa inhibitor indicated for the reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE and reduction in risk of recurrence following initial therapy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
13,571 |
13,571 |
13,571 |
| Total Buy Value |
$0 |
$672,994 |
$672,994 |
$672,994 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
3 |
3 |
3 |
| Total Shares Sold |
0 |
0 |
18,718 |
681,397 |
| Total Sell Value |
$0 |
$0 |
$1,146,397 |
$49,727,684 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
12 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Elkins David V |
EVP, Chief Financial Officer |
• – – |
2020-08-01 |
4 |
D |
$58.66 |
$1,520,233 |
D/D |
(25,916) |
54,782 |
|
- |
|
| Elkins David V |
EVP, Chief Financial Officer |
• – – |
2020-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,402 |
80,698 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2020-07-01 |
4 |
D |
$59.43 |
$265,236 |
D/D |
(4,463) |
4,893 |
|
- |
|
| Hirawat Samit |
EVP,Chief Med.Offr.,Drug Dev. |
• – – |
2020-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,356 |
9,356 |
|
- |
|
| Santiago Karen Murphy |
SVP & Controller |
• – – |
2020-07-01 |
4 |
D |
$59.43 |
$21,811 |
D/D |
(367) |
7,748 |
|
- |
|
| Santiago Karen Murphy |
SVP & Controller |
• – – |
2020-07-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,069 |
8,115 |
|
- |
|
| Paliwal Dinesh C |
Director |
– • – |
2020-06-15 |
4 |
B |
$54.50 |
$499,983 |
D/D |
9,174 |
22,109 |
2.39 |
8% |
|
| Bonney Michael W |
Director |
– • – |
2020-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
558 |
8,650 |
|
- |
|
| Haller Julia A |
Director |
– • – |
2020-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
558 |
6,819 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2020-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
903 |
8,092 |
|
- |
|
| Haller Julia A |
Director |
– • – |
2020-06-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
903 |
6,261 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2020-06-03 |
4 |
D |
$60.21 |
$44,435 |
D/D |
(738) |
7,861 |
|
- |
|
| Eid Joseph |
SVP,Head Glob. Medical Affairs |
• – – |
2020-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,154 |
8,599 |
|
- |
|
| Bonney Michael W |
Director |
– • – |
2020-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,949 |
7,189 |
|
- |
|
| Haller Julia A |
Director |
– • – |
2020-06-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,949 |
5,358 |
|
- |
|
| Dubow Adam |
SVP,ChiefCompliance&EthicsOff. |
• – – |
2020-05-22 |
4 |
S |
$61.01 |
$195,232 |
D/D |
(3,200) |
16,086 |
|
3% |
|
| Schmukler Louis S |
EVP,Pres.,Glob.Prod. & Supply |
• – – |
2020-05-19 |
4 |
S |
$62.68 |
$1,567,000 |
D/D |
(25,000) |
26,777 |
|
5% |
|
| Ahmed Nadim |
EVP and President, Hematology |
• – – |
2020-05-01 |
4 |
D |
$60.26 |
$86,353 |
D/D |
(1,433) |
26,030 |
|
- |
|
| Ahmed Nadim |
EVP and President, Hematology |
• – – |
2020-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,908 |
27,463 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-05-01 |
4 |
D |
$60.26 |
$317,811 |
D/D |
(5,274) |
53,776 |
|
- |
|
| Vessey Rupert |
EVP, Research & Early Dev. |
• – – |
2020-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,707 |
59,050 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2020-03-10 |
4 |
D |
$57.93 |
$116,845 |
D/D |
(2,017) |
7,046 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2020-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
552 |
8,025 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2020-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,063 |
7,778 |
|
- |
|
| Santiago Karen Murphy |
Controller |
• – – |
2020-03-10 |
4 |
D |
$0.00 |
$0 |
D/D |
(39) |
4,649 |
|
- |
|
2225 Records found
|
|
Page 13 of 89 |
|
|
0.35 (0.78%) 
